See the Complete Picture.
Published loading...Updated

First Personalized Gene Therapy Using Base Editing Shows Promising Results in Baby with Rare Disorder

  • In February 2025, a six-month-old infant named KJ Muldoon from Pennsylvania received the first personalized CRISPR gene editing therapy for severe CPS1 deficiency.
  • The therapy aimed to correct KJ's faulty gene that causes a deficiency of an enzyme leading to toxic ammonia build-up and high infant mortality.
  • Within half a year, a medical team from Philadelphia-based institutions developed a tailored gene therapy and administered the initial treatment in February 2025, followed by additional doses in March and April.
  • KJ has improved protein intake, reduced medication, and recovered from illnesses without ammonia spikes, while researchers stress longer monitoring is needed.
  • This milestone suggests personalized base-editing might expand rare disease treatments, though substantial barriers and high costs remain before wider availability occurs.
Insights by Ground AI
Does this summary seem wrong?

236 Articles

All
Left
45
Center
96
Right
22
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 59% of the sources are Center
59% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Nature broke the news in United Kingdom on Thursday, May 15, 2025.
Sources are mostly out of (0)